API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
RSO-021 (thiostrepton) is a novel small molecule, that irreversibly binds to mitochondrial peroxiredoxin 3 (PRX3). It is being evaluated in phase 2 clinical trials for the treatment of malignant pleural mesothelioma and metastatic disease to the lung.
Lead Product(s): Thiostrepton
Therapeutic Area: Oncology Product Name: RSO-021
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024